BSX · News · 20261106N

Liquidity and Capital Position

BOSTON SCIENTIFIC CORP · 2026-11-06 · Importance 59 · Surprise 42

S&P Global Ratings revised Boston Scientific’s outlook to negative from stable, citing commercial headwinds and financial leverage expected to remain stretched through 2028. S&P affirmed the company’s 'A-' issuer credit rating and senior unsecured debt rating. The agency linked leverage pressure to deteriorating top-line momentum and the pending $14.5 billion Penumbra acquisition.